REVITALISE: A Large Observational Study Assessing the Safety and Effectiveness of Vardenafil in Men With Erectile Dysfunction and Metabolic Syndrome

Sexual Medicine - Tập 4 - Trang e135-e144 - 2016
Ridwan Shabsigh1, Andreas Mattern2
1Chairman, Department of Surgery, SBH Health System, Bronx, NY; Professor of Clinical Urology, Cornell University, Ithaca, NY, USA
2Bayer Pharma AG, Berlin, Germany

Tóm tắt

Abstract Introduction Erectile dysfunction (ED) is prevalent in men with metabolic syndrome (MetS); therefore, it is important to characterize ED treatments in this population. Aims To investigate the safety and effectiveness of vardenafil in men with ED and MetS in a clinical setting. Methods REVITALISE is an international, prospective, single-arm, observational study in men with ED and MetS newly prescribed vardenafil. Vardenafil was prescribed at the discretion of the treating physician in line with the marketing authorization. Treatment effectiveness (International Index of Erectile Function [IIEF]) and health-related quality of life (Aging Males' Symptoms Scale) were assessed at treatment initiation, at an optional dose adjustment visit after approximately 4 weeks, and at the end of the observation period (approximately 12 weeks). Main Outcome Measures The primary outcome was an intraindividual improvement in erectile function (EF), defined as an increase of at least four points in the EF domain of the IIEF. Secondary outcomes included assessing normal EF (IIEF-EF score ≥ 26), mild ED (IIEF-EF score = 22–25), and health-related quality of life. Treatment-emergent adverse events were monitored. Results In the intent-to-treat population (n = 1,832, mean age = 54.0 years, mean body mass index = 31.82 kg/m2, Asian 36.8%, white 49.9%, 20.4% with severe ED, 75.6% with mild or moderate ED, 4.0% without ED), 82.4% reported an increase of at least four points in IIEF-EF score. Median IIEF-EF score increased from 15.0 (baseline) to 25.0 at 12 weeks (P < .0001). After treatment, 45.4% and 29.4% (intent-to-treat population) had normal EF and mild ED, respectively. Improvements in the sexual, psychological, and somatic subscales of the Aging Males' Symptoms Scale were found (P < .0001). Treatment-emergent adverse events were reported by 7.19% of patients; there were no serious adverse events related to vardenafil. Conclusion In a clinical setting, men with ED and MetS treated with vardenafil reported improvements in EF and health-related quality of life; and the safety profile of vardenafil was acceptable. REVITALISE demonstrates that vardenafil represents a good treatment option for men with ED and MetS.

Tài liệu tham khảo

Bal, 2007, Prevalence of metabolic syndrome and its association with erectile dysfunction among urologic patients: metabolic backgrounds of erectile dysfunction, Urology, 69, 356, 10.1016/j.urology.2006.09.057 Esposito, 2005, High proportions of erectile dysfunction in men with the metabolic syndrome, Diabetes Care, 28, 1201, 10.2337/diacare.28.5.1201 Kupelian, 2006, Erectile dysfunction as a predictor of the metabolic syndrome in aging men: results from the Massachusetts Male Aging Study, J Urol, 176, 222 Penson, 2003, Do impotent men with diabetes have more severe erectile dysfunction and worse quality of life than the general population of impotent patients?: Results from the Exploratory Comprehensive Evaluation of Erectile Dysfunction (EXCEED) database, Diabetes Care, 26, 1093, 10.2337/diacare.26.4.1093 Walczak, 2002, Prevalence of cardiovascular risk factors in erectile dysfunction, J Gend Specif Med, 5, 19 Corona, 2007, A comparison of NCEP-ATPIII and IDF metabolic syndrome definitions with relation to metabolic syndrome-associated sexual dysfunction, J Sex Med, 4, 789 Kaya, 2015, A comprehensive review of metabolic syndrome affecting erectile dysfunction, J Sex Med, 12, 856 Park, 2011, Prevalence and medical management of erectile dysfunction in Asia, Asian J Androl, 13, 543, 10.1038/aja.2010.131 Hatzimouratidis, Guidelines on male sexual dysfunction: Erectile dysfunction and premature ejaculation. European Association of Urology Montague, The management of erectile dysfunction: an update. American Urological Association Stief, 2004, Sustained efficacy and tolerability with vardenafil over 2 years of treatment in men with erectile dysfunction, Int J Clin Pract, 58, 230, 10.1111/j.1368-5031.2004.00128.x Hellstrom, 2002, Vardenafil for treatment of men with erectile dysfunction: efficacy and safety in a randomized, double-blind, placebo-controlled trial, J Androl, 23, 763 Valiquette, 2005, Sustained efficacy and safety of vardenafil for treatment of erectile dysfunction: a randomized, double-blind, placebo-controlled study, Mayo Clin Proc, 80, 1291, 10.4065/80.10.1291 Donatucci, 2004, Vardenafil improves patient satisfaction with erection hardness, orgasmic function, and overall sexual experience, while improving quality of life in men with erectile dysfunction, J Sex Med, 1, 185 Chen, 2011, The efficacy and safety of vardenafil in East Asian men with erectile dysfunction, J Sex Med, 4, 753 Hatzichristou, 2004, The efficacy and safety of flexible-dose vardenafil (Levitra®) in a broad population of European men, Eur Urol, 45, 634, 10.1016/j.eururo.2004.01.014 Porst, 2003, Efficacy and tolerability of vardenafil for treatment of erectile dysfunction in patient subgroups, Urology, 62, 519, 10.1016/S0090-4295(03)00491-6 Van Ahlen, 2010, The real-life safety and efficacy of vardenafil (REALISE) study: results in men from Europe and overseas with erectile dysfunction and cardiovascular or metabolic conditions, J Sex Med, 7, 3161 Miner, 2008, Vardenafil in men with stable statin therapy and dyslipidemia, J Sex Med, 5, 1455 Goldstein, 2003, Vardenafil, a new phosphodiesterase type 5 inhibitor, in the treatment of erectile dysfunction in men with diabetes: a multicenter double-blind placebo-controlled fixed-dose study, Diabetes Care, 26, 777, 10.2337/diacare.26.3.777 Eardley, 2010, Vardenafil improves erectile function in men with erectile dysfunction and associated underlying conditions, irrespective of the use of concomitant medications, J Sex Med, 7, 244 Shabsigh, 2007, Efficacy of vardenafil for the treatment of erectile dysfunction in men with hypertension: a meta-analysis of clinical trial data, Curr Med Res Opin, 23, 2453, 10.1185/030079907X219616 Van Ahlen, 2005, Safety and efficacy of vardenafil, a selective phosphodiesterase 5 inhibitor, in patients with erectile dysfunction and arterial hypertension treated with multiple antihypertensives, J Sex Med, 2, 856 Schneider, 2011, Efficacy and safety of vardenafil for the treatment of erectile dysfunction in men with metabolic syndrome: results of a randomized, placebo-controlled trial, J Sex Med, 8, 2904 BayerHealthCare. Levitra 5 mg, 10 mg, 20 mg film-coated tablets. Product information. Available at: http://www.medicines.org.uk/emc/medicine/11775. Published 2014. Rosen, 1997, The International Index of Erectile Function (IIEF): a multidimensional scale for assessment of erectile dysfunction, Urology, 49, 822, 10.1016/S0090-4295(97)00238-0 Rosen, 2002, The International Index of Erectile Function (IIEF): a state-of-the-science review, Int J Impot Res, 14, 226, 10.1038/sj.ijir.3900857 Quek, 2002, Reliability and validity of the Malay version of the International Index of Erectile Function (IIEF-15) in the Malaysian population, Int J Impot Res, 14, 310, 10.1038/sj.ijir.3900902 Heinemann, 2003, The Aging Males' Symptoms (AMS) scale: update and compilation of international versions, Health Qual Life Outcomes, 1, 15, 10.1186/1477-7525-1-15 Center for Epidemiology and Health Research (ZEG). AMS Aging Males Symptoms scale. Available at: http://www.aging-males-symptoms-scale.info/languages.htm#notes. Published 2008. Herdman, 1998, A model of equivalence in the cultural adaptation of HRQoL instruments: The universalist approach, Qual Life Res, 7, 323, 10.1023/A:1008846618880 Alberti, 1998, Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus. Provisional report of a WHO consultation, Diabet Med, 15, 539, 10.1002/(SICI)1096-9136(199807)15:7<539::AID-DIA668>3.0.CO;2-S 1999, Comment on the provisional report from the WHO consultation, Diabet Med, 16, 442, 10.1046/j.1464-5491.1999.00059.x Expert Panel on the Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults, 2001, Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III), JAMA, 285, 2486, 10.1001/jama.285.19.2486 Alberti, 2006, Metabolic syndrome—a new world-wide definition. A consensus statement from the International Diabetes Federation, Diabet Med, 23, 469, 10.1111/j.1464-5491.2006.01858.x Yuan, 2016, A meta-regression evaluating the effectiveness and prognostic factors of oral phosphodiesterase type 5 inhibitors for the treatment of erectile dysfunction, Asian J Androl, 18, 60, 10.4103/1008-682X.154304 Tan, 2008, Efficacy and tolerability of vardenafil in Asian men with erectile dysfunction, Asian J Androl, 10, 495, 10.1111/j.1745-7262.2008.00388.x Corona, 2010, Age-related changes in general and sexual health in middle-aged and older men: results from the European Male Ageing Study (EMAS), J Sex Med, 7, 1362 Albersen, 2012, Evaluation and treatment of erectile dysfunction in the aging male: a mini-review, Gerontology, 58, 3, 10.1159/000329598 Shabsigh, 2004, Randomized study of testosterone gel as adjunctive therapy to sildenafil in hypogonadal men with erectile dysfunction who do not respond to sildenafil alone, J Urol, 172, 658
Thông tin
Thông tin xuất bản

Sexual Medicine

Tập 4

e135-e144

Thông tin tác giả